Business Wire

VodafoneZiggo Relies on K2View to Power Combined Customer Repository

29.7.2020 15:00:00 EEST | Business Wire | Press release

Share

K2View, a leading provider of real-time DataOps and data management solutions, today announced that it is powering VodafoneZiggo’s Combined Customer Repository (CCR) solution. In this capacity, K2View Fabric is delivering comprehensive customer and product data across VodafoneZiggo customers.

Achieving a comprehensive view of data across customers and products continues to be a challenge for virtually every organization. This challenge is caused by decades of data management best practices that have resulted in a diverse set of data sources, complicating data management. K2View Fabric takes a fundamentally different approach with the introduction of the patented Digital Entity – a person, place, or thing, recreated digitally out of its data.

“As we approached the merger of VodafoneZiggo, we needed to provide near real-time eligibility checks and initiate benefit provisioning to converged customers with both a fixed and mobile subscription. Before K2View, our legacy CCR led to the ongoing success of the merger; however, there were also some limitations,” said Marc Schmeetz, Program Manager, VodafoneZiggo. “Over time, this legacy CCR system had proven not to have the required flexibility or agility to support future Business demands; further, data updates that were occurring over a 24-hour period or longer were becoming an increasing worrying factor. Due to evolving customer expectations, this processing time window was no longer acceptable, and there was an additional risk when projects changed or added functionality in the previous CCR. To continue to provide excellent customer care, a change needed to be made. But with K2View, there’s no drama. We’ve gone from 24+ hours for updates to having data simply available in minutes or even seconds – we’re happy with how it is performing.”

With K2View powering the CCR, VodafoneZiggo can more easily implement new or changing rules due to their newly improved agility. As a result, the company has an accelerated ability to bring those changes to market.

“By simply enabling us to move with more agility, K2View is helping to open up new opportunities for VodafoneZiggo,” said Reinhard Kreft, IT Director, VodafoneZiggo. “If the improvements in our ability to go to market were not enough, the near real-time eligibility checks and provisioning of benefits boost the customer experience and support our customer care agents. We’re confident that K2View will be able to support our vision, especially as we turn towards building out a true and comprehensive ‘Customer 360’ view.”

About K2View

K2View is a leading provider of advanced data fabric, data integration, and data delivery software that takes the promise of a 360-degree view of data to the next level. Its flagship solution, K2View Fabric, uses patented logical unit technology to enable quick, easy, and secure access and control to all of an organization’s data, no matter how many different systems and data sources it may have. K2View delivers real-time, holistic access and operational insights to whatever data matters most to organizations in any industry, right when they need it, accelerating transformations in customer experience, cloud enablement, operations, IT modernization, and risk and compliance. Learn more at www.k2view.com and follow us at @k2view.

About VodafoneZiggo

VodafoneZiggo is a leading Dutch company that provides fixed, mobile, and integrated communication and entertainment services to consumers and businesses. As of March 31, 2020, VodafoneZiggo has more than 5 million mobile, nearly 4 million TV, nearly 3.4 million fixed broadband internet and 2.4 million fixed telephony subscriptions. VodafoneZiggo is a joint venture by Liberty Global, the largest international TV and broadband internet company, and Vodafone Group, one of the world’s largest telecommunication companies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For more information on K2View, please contact:
Aaron Fullen
K2View
aaron.fullen@k2view.com

For further information on VodafoneZiggo, please contact:
Media Relations
VodafoneZiggo the Netherlands
pers@vodafoneziggo.com
0031 – 88 717 0717

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 18:08:00 EEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubrutinib) plus next-generation BCL2 inhibitor BEQALZI™ (sonrotoclax; ZS), which continue to demonstrate rapid, deep, durable responses across multiple B-cell malignancies. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “BTK inhibition has reshaped the treatment of B-cell cancers, and we believe degradation is the next leap forwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye